WO2008150246A1 - Composition hémostatique à base de plante - Google Patents

Composition hémostatique à base de plante Download PDF

Info

Publication number
WO2008150246A1
WO2008150246A1 PCT/TR2007/000129 TR2007000129W WO2008150246A1 WO 2008150246 A1 WO2008150246 A1 WO 2008150246A1 TR 2007000129 W TR2007000129 W TR 2007000129W WO 2008150246 A1 WO2008150246 A1 WO 2008150246A1
Authority
WO
WIPO (PCT)
Prior art keywords
haemostatic composition
haemostatic
composition according
extracts
bleeding
Prior art date
Application number
PCT/TR2007/000129
Other languages
English (en)
Inventor
Huseyin Cahit Firat
Original Assignee
Ankaferd Ilac Kozmetik Uretim Pazarlama A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankaferd Ilac Kozmetik Uretim Pazarlama A.S. filed Critical Ankaferd Ilac Kozmetik Uretim Pazarlama A.S.
Publication of WO2008150246A1 publication Critical patent/WO2008150246A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • haemostatic products there are various haemostatic products to stop bleeding. When the haemostatic effectiveness of the products is weak, these products need to be changed frequently on the applied site of bleeding. These applications irritate the injured area, restart bleeding and cause pain. Therefore a strong haemostatic composition is needed.
  • This invention due to its strong haemostatic effectiveness, stops or decreases bleeding in a very short time (less than 15 seconds) when applied to bleeding areas that has been injured or burned. It has been proved that, no cytotoxicity and sensitivity occurs at the applied area by the tests done using this composition.
  • This invention describes a strong haemostatic composition that has been prepared by the extraction of herbal drugs from the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris which are suitable for pharmaceutical use.
  • the invention describes the methods, devices and medical equipments that are used for applying this haemostatic composition to the wounds and/or burns or similar damages.
  • the primary object of the invention is haemostatic compositions that has been prepared by the extraction of herbal drugs from the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris which are suitable for pharmaceutical use.
  • haemostatic composition which may include pharmaceutical additives appropriate for the production of gel, cream, ointment, emulsion, suspension, aerosol, wound bandage, tampon etc forms that are intended for use to stop bleeding.
  • Haemostatic composition of the invention can be prepared either by the water extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris all together at suitable proportions or by the water extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris separately and then combining the individual extracts at suitable proportions.
  • compositions can be prepared by using the separate or combined alcohol extracts of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris and/or dry materials obtained by drying the extracts of the same herbs and/or materials isolated from the same herbs and/or materials isolated from the same herbs being sold commercially.
  • Urtica dioica the separate or combined alcohol extracts of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris and/or dry materials obtained by drying the extracts of the same herbs and/or materials isolated from the same herbs and/or materials isolated from the same herbs being sold commercially.
  • Above ground parts and roots of the herb can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product.
  • Urtica dioica contains amines (i.e. histamine), formic acid, serotonins, flavonoids (i.e. quercitol and rutin), glycosides, tannins, carotenes and vitamin C in its structure.
  • Urtica dioica is a herb type commonly used for urinary tract infections, rheumatic diseases, prostate adenomas and difficulty in urination.
  • Above ground parts and roots of the herb can either be prepared fresh or dry or they can be found as extracts obtained in different ways as commercial product.
  • Glycyrrhiza glabra contains glycyrrhizic acid and flavonoids (i.e. liquiritine and isoliquiritine) in its structure. Glycyrrhiza glabra has expectorant effect. Besides it is widely used for gastric and duodenal ulcers.
  • Thymus vulgaris contains high amounts of phenolic compounds (thymole and carvacrole) in its structure. These compounds are strong antiseptics. Due to pulmonary discharge of them, they are used as respiratory tract antiseptic. Thymus vulgaris is used as respiratory tract antiseptic and anti-tussive in common cold diseases.
  • phenolic compounds thymole and carvacrole
  • Thymus vulgaris is used as respiratory tract antiseptic and anti-tussive in common cold diseases
  • the herbs that are found in this haemostatic composition are also found in a variety of orally administered herbal drugs. Therefore although there is no concern about safety and it is well known that it has no toxicity on human, the haemostatic composition's safety has been proven with the tests shown below: Cytoxicity Test
  • Haemostatic composition when evaluated on albino rabbits and guinea pigs according to international methods TS 5298 EN ISO 10993-1 (Biological evaluation of medical devices) and EN ISO 10993-10:2002 (Tests of cytotoxicity: in vitro methods) the composition was found no to have irritation and/or sensitivity effects.
  • Haemostatic composition when evaluated according to international methods EN ISO 10993-1 (Biological evaluation of medical devices) and EN ISO 10993-4:1999 (Biological evaluation of medical devices: Selection of tests for interaction with blood) was shown to stop bleeding effectively, shorter than one second. It has been concluded that, haemostatic product can be used effectively in skin and mucosal bleedings.
  • Haemostatic composition of the invention can be prepared either by the extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia off ⁇ cinarum and Thymus vulgaris all together at suitable proportions or by the extraction of the herbal drugs of the identified parts of Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum and Thymus vulgaris separately and then combining the individual extracts at suitable proportions.
  • a sample composition that is prepared for direct applying, spraying or applying of impregnated dressing material to injured skin or mucosa is shown below:
  • compositions of the invention can be prepared with different amounts, proportions and concentrations of drugs according to intended application and case.
  • composition of the invention is used as haemostatic. This composition is used to control, decrease or stop the bleeding by applying to wounded areas, injured areas due to accidents and surgical operations, due to catheter application or dialysis needle insertion. Another application area for this composition is to control or decrease the damage due to dental or surgical operations or control or decrease the bleedings that accidentally occurs.
  • Compositions, devices and applications of the invention can be used for dental bleedings, nasal bleedings, accidental bleedings due to minor cuts and cuts in haemophiliac patients (i.e. shaving cuts, minor cuts due to using personal hygienic tools, playing injuries, etc), wounds, circumcision wounds, surgical cuts and other minor cuts and injuries.
  • Composition of the invention can also be applied to burns, necrotic and atrophic ulcers or wounds such as foot wounds seen in diabetic patients. It can stop bleeding and decrease the wound and damage in the injured area.
  • Composition of the invention can include or can be used with epinephrine for some burns and wounds. Alternatively or additionally it can also be prepared or it can be used with using different antimicrobial and/or antiseptic agents. It can include chlorhexidine, furazidine, propolis, mexidole or a mixture thereof. For burns the ones that include hyaluronic acid, propolis and/or papaya are especially useful. For minor burns the materials that are prepared from non-cotton are appropriate. These dressing materials can include biocompatible polymers (hyaluronic acid and/or alginates) and a therapeutic agent.
  • composition of the invention when used directly or with accessory devices was found to be effective in a variety of minor superficial bleedings.
  • Haemostatic composition can be applied to bleeding site directly, as well as gently applying pressure on dressings by hand, elastic bandage, or plasters.
  • haemostatic composition can stop bleeding shorter than 15 seconds time. It was shown that, in different trials using different haemostatic composition, accessory devices and applications, this time can be prolonged to 50 seconds depending on the severity of bleeding. In some cases haemostatic composition or the device can be left on the injured area for minutes, hours or days. In this case, it is recommended to replace the device including haemostatic composition few times.
  • Haemostatic composition and devices also includes pharmaceutical formulations for topical and Trans dermal applications. For example by using haemostatic composition as an active ingredient with other contributory pharmaceutical compounds ointment, cream, paste, lotion, gel, powder, solution, spray or inhalants can be formulated.
  • haemostatic composition can be used with devices or materials that make the haemostatic composition to diffuse to the injured area.
  • Some of these application methods are; applying the product by using cotton or dressings made from other materials that are similar to cotton.
  • Injured area can be covered by a dressing that is produced from appropriate material and impregnated with haemostatic composition or this area can be covered with elastic bandage impregnated with haemostatic composition.
  • Haemostatic composition can be applied to injured area with dressings that are produced using all kind of suitable material. When needed dressings produced from air permeable material can be used or absorbent material can be used to eliminate fluid in the injured area.
  • haemostatic material to the injured area
  • dressings made from cotton or non- cotton material can be used.
  • non-cotton dressing cellulose cellulose fibbers or viscon can be used.
  • the products including haemostatic composition can be sterilized by irradiation (gamma irradiation) or ethylene oxide.
  • Container that protects the sterile material from contamination can be covered using water resistant aluminium or plastic material.
  • haemostatic composition can be formulated with biocompatible polymers and gels.
  • Biocompatible polymers and gels will help coagulation by absorbing the fluid in the wound; thus increase the effectiveness of the product.
  • These polymers are agar, agarose, carrageen, alginic acid and/or derivatives of alginic acid, hyaluronic acid and/or derivatives of hyaluronates, chitin, chitosan, fibrin, dextran and or dextran copolymers, polyvinylpyrrolidone, waxes, cellulose and/or derivatives of cellulose such as sodium carboxymethyl cellulose, ethyl cellulose and/or cellulose acetate, glycols such as propylene glycol or polyethylene glycol and the mixture of these.
  • hydrophilic biopolymers can also be used.
  • these can be hydrophilic diols, hydrophilic diamines or the combination of these.
  • haemostatic composition can include hydro gel.
  • hydro gel can be cross-linked keratin, polymethyl methacrylate, polyethylene glycol, ethylene/vinyl alcohol copolymer, polyalcoxy alkyl (meth)acrylate or the combination of these.
  • Haemostatic composition when needed can include one or more pharmaceutical active ingredients.
  • it can include an antimicrobial, an antibiotic, an antimycobacterial, an antifungal, an antiviral, and local anaesthetics such as lidocaine, procaine, tetracaine, dibucain, an analgesic, an antioxidant, an antiseptic, a vitamin or the combination of these .

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition hémostatique qui est extraite de parties spécifiques des plantes médicinales Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum et Thymus vulgaris. Ladite composition est capable d'arrêter les hémorragies dans un très bref délai.
PCT/TR2007/000129 2007-06-07 2007-11-06 Composition hémostatique à base de plante WO2008150246A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR200703933 2007-06-07
TR2007/03933 2007-06-07

Publications (1)

Publication Number Publication Date
WO2008150246A1 true WO2008150246A1 (fr) 2008-12-11

Family

ID=38969381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2007/000129 WO2008150246A1 (fr) 2007-06-07 2007-11-06 Composition hémostatique à base de plante

Country Status (1)

Country Link
WO (1) WO2008150246A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101889953A (zh) * 2010-07-29 2010-11-24 李国钧 药烟液、药烟气制作装置及制作方法
US8623842B2 (en) 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
US9061087B2 (en) 2008-03-04 2015-06-23 Hemostasis, Llc Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor
CN106236811A (zh) * 2015-06-11 2016-12-21 黑龙江康普生物科技有限公司 消毒止血止痛防水液体膜及制备方法
IT201600070397A1 (it) * 2016-07-06 2018-01-06 Lifecode Supplements Di Marcelli Valerio Composizione a base di vegetali a foglia verde per aumentare i livelli corporei di ossido nitrico

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO83870A2 (fr) * 1982-05-17 1984-04-12 Intreprinderea De Produse Cosmetice "Nivea",Ro Prepare hytoterapeutique pour le traitement de l'alveolite poste0traction
EP0341795A1 (fr) * 1988-05-09 1989-11-15 Rodriso Holding B.V. Produits de soins buccaux
RO103501A2 (en) * 1989-01-18 1991-12-02 Plafar Cluj Napoca Medicinal mouth water concentrate
JP2004210757A (ja) * 2003-01-07 2004-07-29 Kenji Omura 歯磨に塩と生姜から搾り出した液を混ぜ合わせて作った歯磨ソルジャー。
WO2006067549A1 (fr) * 2004-12-20 2006-06-29 Koletex, Limited Liability Company Composition hemostatique, appareil et procedes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO83870A2 (fr) * 1982-05-17 1984-04-12 Intreprinderea De Produse Cosmetice "Nivea",Ro Prepare hytoterapeutique pour le traitement de l'alveolite poste0traction
EP0341795A1 (fr) * 1988-05-09 1989-11-15 Rodriso Holding B.V. Produits de soins buccaux
RO103501A2 (en) * 1989-01-18 1991-12-02 Plafar Cluj Napoca Medicinal mouth water concentrate
JP2004210757A (ja) * 2003-01-07 2004-07-29 Kenji Omura 歯磨に塩と生姜から搾り出した液を混ぜ合わせて作った歯磨ソルジャー。
WO2006067549A1 (fr) * 2004-12-20 2006-06-29 Koletex, Limited Liability Company Composition hemostatique, appareil et procedes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 198438, Derwent World Patents Index; AN 1984-235461, XP002466824 *
DATABASE WPI Week 199325, Derwent World Patents Index; AN 1993-203503, XP002466823 *
DATABASE WPI Week 200452, Derwent World Patents Index; AN 2004-538855, XP002467362 *
DATABASE XPTK NISCAIR New Delhi India; 1999, "Draksadiyogah", XP018003691 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623842B2 (en) 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
US9649482B2 (en) 2006-09-27 2017-05-16 Hemostasis, Llc Hemostatic agent and method
US10744310B2 (en) 2006-09-27 2020-08-18 Hemostasis, Llc Hemostatic agent and method
US9061087B2 (en) 2008-03-04 2015-06-23 Hemostasis, Llc Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor
CN101889953A (zh) * 2010-07-29 2010-11-24 李国钧 药烟液、药烟气制作装置及制作方法
CN101889953B (zh) * 2010-07-29 2013-05-29 李国钧 药烟液、药烟气制作装置及制作方法
CN106236811A (zh) * 2015-06-11 2016-12-21 黑龙江康普生物科技有限公司 消毒止血止痛防水液体膜及制备方法
IT201600070397A1 (it) * 2016-07-06 2018-01-06 Lifecode Supplements Di Marcelli Valerio Composizione a base di vegetali a foglia verde per aumentare i livelli corporei di ossido nitrico

Similar Documents

Publication Publication Date Title
Khorasani et al. Aloe versus silver sulfadiazine creams for second-degree burns: a randomized controlled study
Davis et al. Wound healing. Oral and topical activity of Aloe vera
US20060105000A1 (en) Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil
US9011901B2 (en) Method of promoting hemostasis by using a dressing comprising extract of chamomile and nettle
RU2571063C2 (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
CA2899661A1 (fr) Compositions et procedes pour traiter des plaies superficielles
WO2010062581A2 (fr) Composition botanique pour une réparation cutanée optimisée et utilisations associées
EP2896396A1 (fr) Formulation à base de plantes médicinales topiques pour le traitement des plaies topiques
AU2007231781B2 (en) Method and device for treating bursitis
WO2008150246A1 (fr) Composition hémostatique à base de plante
US20200405637A1 (en) Oil-based wound care compositions and methods
Jacobsen Topical Wound Treatments and Wound‐Care Products
EA023321B1 (ru) Набор для лечения и/или предотвращения кожных язв
JP2022522567A (ja) 真皮保護剤および担体
US8900601B2 (en) Permeable mixtures, methods and compositions for the skin
US8173183B2 (en) Mucosal membrane healant and moisturizer
KR102445058B1 (ko) 사용성 및 위생성이 향상된 롤 타입 연고
RU2128990C1 (ru) Мазь противовоспалительная и ранозаживляющая "вундэхил"
RU2188016C1 (ru) Клеевая лечебно-профилактическая композиция
RU2810444C1 (ru) Способ лечения вульгарных и подошвенных бородавок
WO2024049361A1 (fr) Mélanges de compositions à base de cannabinoïdes et de substances actives provenant d'autres genres pour des applications médicales et associés
Gopinathan et al. Effect of Calendula officinalis in burn wounds of bovine calves and heifers
Vinubharathi et al. A CONCEPTUAL STUDY ON THE ROLE OF SIDDHA PARASURGICAL PROCEDURES IN THE MANAGEMENT OF CHRONIC WOUND
KR20220144070A (ko) 계란 껍데기 분말을 유효 성분으로 함유하는 화상 치료용 조성물
WO2020044368A1 (fr) Moullava spicata (wakeri) pour la cicatrisation des plaies

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07835629

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07835629

Country of ref document: EP

Kind code of ref document: A1